Literature DB >> 9177865

Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow.

M Weinreb1, I Suponitzky, S Keila.   

Abstract

Prostaglandin E2 (PGE2) possesses significant anabolic properties when administered systemically (i.e., it increases bone formation and, consequently, bone mass). We recently characterized the effects of a 3 week administration of 6 mg/kg PGE2 into young rats and showed it increases cortical and cancellous bone mass and mechanical strength in long bones and bone density in the calvaria. We also found that a single dose of PGE2 induces the expression of early-response genes (c-fos, c-jun, and egr-1) in bone marrow cells within these two types of bone. These observations, together with findings by others of new cancellous bone formation in PGE2-treated animals, suggested that recruitment of osteoblasts from their precursors is a major mechanism of the anabolic effect of PGE2. To test this hypothesis directly, we injected PGE2 (6 mg/kg) or vehicle into 4-week-old rats for 2 weeks and then assessed the osteogenic potential of bone marrow in an ex vivo culture system. Primary and first-passage bone marrow cultures were established in the presence of beta-glycerophosphate, ascorbate, and dexamethasone, and osteogenic differentiation was measured by bone nodule formation and alkaline phosphatase activity. This regimen increased bone mass expressed as femoral ash weight by 4.7% and tibial cancellous bone area by 38.3%. Nodule formation at 21 days was increased in both primary and first-passage cultures from PGE2-treated rats despite seeding of the same number of marrow cells. Alkaline phosphatase activity was elevated in both primary and first-passage cultures from PGE2-treated rats beginning 6-10 days after culture initiation. Cell proliferation was only slightly elevated in cultures from PGE2-treated rats. These data strongly suggest that in vivo administration of PGE2 induces the proliferation or differentiation of osteoprogenitor cells in bone marrow, and this effect takes a major part in its anabolic effect in vivo.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177865     DOI: 10.1016/s8756-3282(97)00033-1

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  23 in total

1.  Basal bone phenotype and increased anabolic responses to intermittent parathyroid hormone in healthy male COX-2 knockout mice.

Authors:  Manshan Xu; Shilpa Choudhary; Olga Voznesensky; Qi Gao; Douglas Adams; Vilmaris Diaz-Doran; Qian Wu; David Goltzman; Lawrence G Raisz; Carol C Pilbeam
Journal:  Bone       Date:  2010-05-13       Impact factor: 4.398

2.  PGE2 Receptor Subtype 1 (EP1) Regulates Mesenchymal Stromal Cell Osteogenic Differentiation by Modulating Cellular Energy Metabolism.

Authors:  Marina Feigenson; Roman A Eliseev; Jennifer H Jonason; Bradley N Mills; Regis J O'Keefe
Journal:  J Cell Biochem       Date:  2017-05-31       Impact factor: 4.429

3.  Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation.

Authors:  Keiji Yoshida; Hiroji Oida; Takuya Kobayashi; Takayuki Maruyama; Masaharu Tanaka; Teruaki Katayama; Kojiro Yamaguchi; Eri Segi; Tadao Tsuboyama; Mutsumi Matsushita; Kosei Ito; Yoshiaki Ito; Yukihiko Sugimoto; Fumitaka Ushikubi; Shuichi Ohuchida; Kigen Kondo; Takashi Nakamura; Shuh Narumiya
Journal:  Proc Natl Acad Sci U S A       Date:  2002-03-26       Impact factor: 11.205

4.  Prostacyclin regulates bone growth via the Epac/Rap1 pathway.

Authors:  Michele R Hutchison; Perrin C White
Journal:  Endocrinology       Date:  2014-11-18       Impact factor: 4.736

5.  Estrogen receptor-β regulates mechanical signaling in primary osteoblasts.

Authors:  Alesha B Castillo; Jason W Triplett; Fredrick M Pavalko; Charles H Turner
Journal:  Am J Physiol Endocrinol Metab       Date:  2014-03-11       Impact factor: 4.310

Review 6.  Calcium-independent phospholipases A2 and their roles in biological processes and diseases.

Authors:  Sasanka Ramanadham; Tomader Ali; Jason W Ashley; Robert N Bone; William D Hancock; Xiaoyong Lei
Journal:  J Lipid Res       Date:  2015-05-28       Impact factor: 5.922

7.  Age-related changes in bone morphology are accelerated in group VIA phospholipase A2 (iPLA2beta)-null mice.

Authors:  Sasanka Ramanadham; Kevin E Yarasheski; Matthew J Silva; Mary Wohltmann; Deborah Veis Novack; Blaine Christiansen; Xiaolin Tu; Sheng Zhang; Xiaoyong Lei; John Turk
Journal:  Am J Pathol       Date:  2008-03-18       Impact factor: 4.307

8.  The effect of simvastatin on the proliferation and differentiation of human bone marrow stromal cells.

Authors:  Ki Hyun Baek; Won Young Lee; Ki Won Oh; Hyun Jung Tae; Jung Min Lee; En Jung Lee; Je Ho Han; Moo Il Kang; Bong Yun Cha; Kwang Woo Lee; Ho Young Son; Sung Koo Kang
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

9.  Cyclooxygenase-2 gene disruption promotes proliferation of murine calvarial osteoblasts in vitro.

Authors:  Zheng Xu; Shilpa Choudhary; Yosuke Okada; Olga Voznesensky; Cynthia Alander; Lawrence Raisz; Carol Pilbeam
Journal:  Bone       Date:  2007-03-21       Impact factor: 4.398

10.  Internal prostaglandin synthesis augments osteoprotegerin production in human gingival fibroblasts stimulated by lipopolysaccharide.

Authors:  M Kiji; T Nagasawa; D Hormdee; R Yashiro; H Kobayashi; K Noguchi; H Nitta; Y Izumi; I Ishikawa
Journal:  Clin Exp Immunol       Date:  2007-06-05       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.